Transaction DateRecipientSharesTypePriceValue
23rd June 2020Maky Zanganeh1,193Open or private purchase$10.70$12,767.13
17th June 2020Maky Zanganeh7,950Open or private purchase$7.01$55,729.50
15th June 2020Mitchell E. Levinson127Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$890.27
15th June 2020Darrin Uecker8,563Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$60,026.63
15th June 2020Robert W Duggan2,507,112Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$17,574,855.12
15th June 2020Mitchell E. Levinson714Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$5,005.14
15th June 2020Maky Zanganeh2,050Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$14,370.50
15th June 2020Robert W Duggan54,761Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$383,874.61
15th June 2020Maky Zanganeh20,000Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$140,200.00
15th June 2020Mitchell E. Levinson5,713Exercise of in-the-money or at-the-money derivatives securities (usually options)$7.01$40,048.13
Pulse Biosciences
Pulse Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Pulse Biosciences, Inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.


Ticker: PLSE
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1625101
Employees: 82
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $38 M (0%)
Assets, Current: $39 M (46%)
Property, Plant and Equipment, Net: $3 M (0%)
Other Assets, Noncurrent: $365 Th (-26%)
Assets: $58 M (39%)
Accounts Payable, Current: $1 M (-24%)
Accrued Liabilities, Current: $3 M (0%)
Liabilities, Current: $5 M (9%)
Liabilities: $16 M (43%)
Common Stock, Value, Issued: $25 Th (19%)
Common Stock, Shares, Issued: $25 Th (20%)
Additional Paid in Capital, Common Stock: $188 M (22%)
Retained Earnings (Accumulated Deficit): $146 M (18%)
Stockholders' Equity (Parent): $42 M (0%)
Liabilities and Equity: $58 M (39%)
Research and Development: $6 M (-51%)
General and Administrative Expenses: $5 M (-51%)